
The COVID-19 pandemic accelerated vaccinology progress, driving rapid vaccine development for infectious and non-infectious diseases. However, challenges persist: malaria, HIV, and dengue lack fully effective vaccines, whereas influenza and tuberculosis face waning efficacy. Emerging pathogens and drug-resistant...

Randomized trials comparing new vaccines against tuberculosis for use in neonates and infants, for whom Bacille Calmette-Guérin vaccination is established practice, are using tuberculosis infection as the primary endpoint in a non-inferiority design. Markers of tuberculosis infection have imperfect...

Pneumococcal vaccination is essential for patients with inflammatory bowel diseases (IBD), but its efficacy is reduced in those on antitumor necrosis factor (TNF) or immunosuppressive therapy. This study compared immune responses to standard versus intensified pneumococcal vaccination strategies in IBD...

Hepatitis B infection remains an important global public health problem with significant morbidity and mortality. It is estimated that 2 billion people have evidence of past or present infection with hepatitis B virus (HBV) worldwide [1, 2]. The World Health Organization (WHO) estimated that 296 million...

The success of COVID-19 vaccination is linked to trust, hesitancy, and confidence. Racial discrimination impacts vaccine hesitancy and trust, particularly in racialized groups. This study investigates factors influencing COVID-19 vaccine confidence among Canadian parents from different racial groups,...